# The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover

> **NCT04403698** · PHASE2 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 30 (actual)

## Conditions studied

- Erosive Osteoarthritis

## Interventions

- **DRUG:** Alendronate Effervescent Oral Tablet

## Key facts

- **NCT ID:** NCT04403698
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-13
- **Primary completion:** 2022-03-09
- **Final completion:** 2022-03-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-12-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04403698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04403698, "The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04403698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*